Company Overview and News

 
KLCI seen trading range bound, hurdle at 1,790

2018-10-07 theedgemarkets
KUALA LUMPUR (Oct 8): Sentiment at the local market is seen dampened today, tracking the slump at most global markets last Friday, and the FBM KLCI is expected to trade range bound with hurdle at 1,790 points.
0049 0008 8664 7374

 
Inta Bina, Oceancash, EA Technique, MHB, MyEG, S P Setia, SimeProp, Tien Wah, Willowglen and Zelan

2018-10-05 theedgemarkets
KUALA LUMPUR (Oct 5): Based on corporate announcements and news flow today, companies that may be in focus on Monday (Oct 8) may include the following: Inta Bina Group Bhd, Oceancash Pacific Bhd, EA Technique Bhd, Malaysia Marine Heavy Engineering Holdings Bhd, My EG Services Bhd, S P Setia Bhd, Sime Darby Property Bhd, Tien Wah Press Holdings Bhd, Willowglen MSC Bhd and Zelan Bhd.
0049 0008 8664 DONGY BSMAF 7374 1818

 
Tien Wah to dispose of Australian land for RM65m

2018-10-05 theedgemarkets
KUALA LUMPUR (Oct 5): Tien Wah Press Holdings Bhd’s Australian unit is disposing of a parcel of land in New South Wales, along with a building erected on it, for A$22.02 million (RM65.18 million).
7374

 
KLCI pares loss as select blue chips lend support

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): The FBM KLCI pared some of its loss at midday break today, against a backdrop of struggling regional markets.
HLFBF BRDBF 7036 1082 5681 6432 BATS 4162 7374 5256 5199 5210 1783 5029 3867 SGPBY 6888 AXXTF 5827 1902 HIPEF GEBHF 3719

 
KLCI remains firmly above 1,800-level

2018-09-21 theedgemarkets
KUALA LUMPUR (Sept 21): The FBM KLCI remained firmly above the 1,800-point level at mid-morning and was up 0.37%, tracking the gains at regional markets.
HLFBF 7084 7052 1082 BATS 4162 7374 0089 5139 KLKBY 2445 3301 7216 0900 0026 2836

 
Dufu, Frontken, Tien Wah, Hartalega, Uzma, Inta Bina, Advancecon, Three-A, KKB Engineering, Versatile Creative and MISC

2018-08-07 theedgemarkets
KUALA LUMPUR (Aug 7): Based on corporate announcements and news flow today, stocks in focus tomorrow may include the following: Dufu Technology Corp Bhd, Frontken Corp Bhd, Tien Wah Press Holdings Bhd, Hartalega Holdings Bhd, Uzma Bhd, Inta Bina Group Bhd, Metronic Global Bhd, Advancecon Holdings Bhd, Three-A Resources Bhd, KKB Engineering Bhd, Versatile Creative Bhd and MISC Bhd.
0012 4995 5347 TNABY TNABF 5168 7374 9466 0043 7233 HRGHY

 
Tien Wah returns to profit in 2Q after closing Australian ops

2018-08-07 theedgemarkets
PETALING JAYA (Aug 7): After four consecutive loss-making quarters, Tien Wah Press Holdings Bhd has returned to the black with a net profit of RM3.81 million in its second quarter ended June 30, 2018 (2QFY18), despite a 15% year-on-year decline in revenue to RM92 million.
BSMAF 7374 1818

 
KLCI reverses loss, edges up in line with region

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 1): The FBM KLCI reversed its earlier loss and climbed into positive territory at the midday break today, tracking gains at the regional markets.
HLFBF 7036 7374 5134 GMALY 2852 5029 5347 0035 4715 TNABY 5208 PNAGF 1929 GMALF 1082 ORHLF 6033 7123 5436 4006 PNADF 0026 5819 TNABF

 
KLCI pares gains in line with shaky regional markets

2018-07-04 theedgemarkets
KUALA LUMPUR (July 4): The FBM KLCI pared some of its gains at mid-morning today in line with the shaky regional markets, as mounting worries of an escalating U.S.-China trade spat kept global investors on tenterhooks.
7084 4065 BATS 4162 1163 7374 7055 0120 KLKBY 5139 2445 4863 3867 0037 0900 0026 MYTEF 3719

 
Trading ideas: Crest Builder, Pasukhas, Tien Wah, PUC, Comintel

2018-03-21 thestar.com.my
KUALA LUMPUR: JF Apex Research expects Crest Builder Holdings Bhd , Pasukhas Group Bhd , Tien Wah Press Holdings Bhd , PUC Bhd and Comintel Corp Bhd to be among the stocks to watch today.
0177 8591 7374

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...